News | News By Subject | News by Disease News By Date | Search News

Basal cell carcinoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Pivotal Data For Novartis AG (NVS)'s LDE225 Promising In Phase 2 Basal Cell Carcinoma Trial     6/2/2014
Novartis AG (NVS)'s Experimental Skin Cancer Drug Meets Primary Endpoint In Pivotal Phase 2 Trial     2/21/2014
Roche (RHHBY) Wins Conditional EU Approval for Cancer Drug Erivedge     7/15/2013
FDA Approves Genentech (RHHBY)'s Erivedge (Vismodegib) Capsule, the First Medicine for Adults with Advanced Basal Cell Carcinoma     1/31/2012
Genentech (RHHBY) Skin Cancer Drug Gets FDA Priority Review     11/10/2011

News from Around the Web

Press Releases
Ascend Biopharmaceuticals Announces Encouraging Phase I/IIa Interim Results Of ASN-002 Treatment Of Nodular Basal Cell Carcinoma (nBCC)     11/8/2016
HedgePath Pharmaceuticals Release: FDA Grants Orphan Drug Designation to SUBA-Itraconazole For Treatment Of Patients With BCCNS     6/2/2016
Biofrontera AG Announces Full Results Of Phase III Clinical Trial Evaluating BF-200 ALA For Treatment Of Basal Cell Carcinoma (BCC)     3/7/2016
HedgePath Pharmaceuticals Launches Clinical Trial For Its Proposed Cancer Treatment     8/21/2015
Biosceptre Announces Positive Phase I Results For BIL-010t To Treat Basal Cell Carcinoma     7/23/2014
Cannabis Science Inc. Initiates Preclinical Investigation of CS-TATI-1 for European Studies for Squamous/Basal Cell Carcinomas and Kaposi's Sarcoma     9/24/2012
Curis, Inc. (CRIS) Announces Publication of Erivedge(TM) Data in The New England Journal of Medicine     6/7/2012
Cannabis Science Inc. Reports Success for 4th Brand New Self-Administering Cancer Patient     2/2/2012
Curis, Inc. (CRIS) Announces Collaborator Roche (RHHBY)’s Submission of Marketing Authorization Application for Vismodegib in Advanced Basal Cell Carcinoma     12/22/2011
Curis, Inc. (CRIS) Announces FDA Acceptance and Priority Review of NDA for Vismodegib as Treatment for Advanced Basal Cell Carcinoma     11/9/2011
Curis, Inc. (CRIS) Announces Genentech (RHHBY)'s Initiation of Phase II Trial for GDC-0449 in Operable Basal Cell Carcinoma     10/11/2010
Curis, Inc. (CRIS) Announces IND Filing For Skin Cancer; Drug Candidate For Basal Cell Carcinoma Under Co-Development By Genentech, Inc. (DNA) And Curis     4/1/2005
Peplin Biotech (AU:PEP) And Allergan Inc. (AGN) Initiate Clinical Trials For PEP005     8/30/2004
Peplin Biotech (AU:PEP) Announces Filing Of IND     3/23/2004

//-->